Ocean Biomedical Stock Total Asset
| OCEA Stock | 1.01 0.02 2.02% |
Ocean Biomedical fundamentals help investors to digest information that contributes to Ocean Biomedical's financial success or failures. It also enables traders to predict the movement of Ocean Stock. The fundamental analysis module provides a way to measure Ocean Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ocean Biomedical stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 127.5 M | 133.9 M |
Ocean | Total Asset |
Ocean Biomedical Company Total Asset Analysis
Ocean Biomedical's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Ocean Biomedical Total Asset | 110.91 M |
Most of Ocean Biomedical's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ocean Biomedical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Ocean Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Ocean Biomedical is extremely important. It helps to project a fair market value of Ocean Stock properly, considering its historical fundamentals such as Total Asset. Since Ocean Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ocean Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ocean Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Ocean Total Assets
Total Assets |
|
Based on the latest financial disclosure, Ocean Biomedical has a Total Asset of 110.91 M. This is 98.53% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The total asset for all United States stocks is 99.62% higher than that of the company.
Ocean Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ocean Biomedical's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ocean Biomedical could also be used in its relative valuation, which is a method of valuing Ocean Biomedical by comparing valuation metrics of similar companies.Ocean Biomedical is currently under evaluation in total asset category among its peers.
Ocean Fundamentals
| Return On Asset | -6.82 | ||||
| Current Valuation | 49.44 M | ||||
| Shares Outstanding | 34.65 M | ||||
| Shares Owned By Insiders | 71.98 % | ||||
| Shares Owned By Institutions | 11.62 % | ||||
| Number Of Shares Shorted | 183.68 K | ||||
| Price To Book | 100.67 X | ||||
| EBITDA | (957.74 K) | ||||
| Net Income | (958.43 K) | ||||
| Total Debt | 2.15 M | ||||
| Book Value Per Share | (2.21) X | ||||
| Cash Flow From Operations | (747.3 K) | ||||
| Short Ratio | 4.31 X | ||||
| Earnings Per Share | (2.75) X | ||||
| Target Price | 18.5 | ||||
| Beta | 1.51 | ||||
| Market Capitalization | 34.3 M | ||||
| Total Asset | 110.91 M | ||||
| Retained Earnings | (2.77 M) | ||||
| Working Capital | (3 M) | ||||
| Net Asset | 110.91 M |
About Ocean Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ocean Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocean Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocean Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| AVAV | AeroVironment | |
| ELVN | Enliven Therapeutics | |
| NFLX | Netflix |
Check out Ocean Biomedical Piotroski F Score and Ocean Biomedical Altman Z Score analysis. For information on how to trade Ocean Stock refer to our How to Trade Ocean Stock guide.You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocean Biomedical. If investors know Ocean will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocean Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.75) | Return On Assets (6.82) |
The market value of Ocean Biomedical is measured differently than its book value, which is the value of Ocean that is recorded on the company's balance sheet. Investors also form their own opinion of Ocean Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Ocean Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocean Biomedical's market value can be influenced by many factors that don't directly affect Ocean Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocean Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocean Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocean Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.